What do systematic reviews say?

d4T vs AZT

d4T showed no clear difference in clinical progression compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.78 [0.28, 2.13]
  7 studies · 719 participants
  Low

d4T vs AZT

d4T showed no clear difference in severe adverse events compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 1.17 [0.97, 1.4]
  9 studies · 1363 participants
  Low

d4T vs AZT

d4T showed no clear difference in virologic response compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 1.03 [0.88, 1.19]
  12 studies · 2157 participants
  Low

d4T vs AZT

d4T showed no clear difference in adherence/tolerability/retention compared with AZT (low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.94 [0.84, 1.05]
  12 studies · 2157 participants
  Low

d4T vs AZT

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1537 participants
  Low

d4T vs AZT

It is very uncertain whether d4T changes drug resistance compared with AZT (very low certainty).

• Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
  RR 0.66 [0.25, 1.73]
  1 study · 174 participants
  Very low

TDF vs AZT

TDF showed no clear difference in serious adverse events compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 0.92 [0.6, 1.43]
  2 studies · 586 participants
  High

TDF vs AZT

TDF showed no clear difference in virologic response compared with AZT (high certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 2.04 [0.17, 24.84]
  2 studies · 586 participants
  High

TDF vs AZT

TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 1.17 [1.06, 1.29]
  2 studies · 586 participants
  Moderate

TDF vs AZT

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 515 participants
  Moderate

TDF vs AZT

It is very uncertain whether TDF changes drug resistance compared with AZT (very low certainty).

• Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one… 2010 · Cochrane Headline outcomes only
  RR 20.43 [1.24, 335.9]
  1 study · 71 participants
  Very low